Juniper invests in mixer tech for UK plant

By Staff Reporter

- Last updated on GMT

iStock/robynmac
iStock/robynmac

Related tags Pharmacology

Juniper Pharma Services has upped mixing capacity at its facility in Nottingham, UK to give it the ability to support Phase III studies of topical and semi-solid products.

The UK-based contract manufacturing organization (CMO) – a subsidiary of Nasdaq-listed Juniper Pharmaceuticals​ – has bought, installed and validated a Becomix homogenizer. The technology will be used to make creams, ointments and semi-solids for clinical trials.

Claire Madden-Smith, SVP at Juniper, said: “This addition to our capabilities enables us to develop topical products on a larger scale and to cater for our clients’ supply needs from first-in-man studies up to and including Phase III, with a commercially replicable process in place​.

At the end of last year Juniper bought a Xcelodose ​powder micro-dosing system for the facility and earlier this month it ordered a PSD-1 GEA Niro spray dryer for the Nottingham. On both occasions it said customer demand had prompted the investment.

The mixer was also bought with clients in mind according to Madden-Smith.

We are no stranger to aiding clients with challenging formulations and so the installation of Becomix simply bolsters our ability to support drug development companies that are developing creams, ointments, and semi-solid products, both simple and complex​.”

Related news

Show more

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Follow us

Products

View more

Webinars